{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T05:46:19Z","timestamp":1782193579106,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003130","name":"FWO","doi-asserted-by":"publisher","award":["11PGA24N"],"award-info":[{"award-number":["11PGA24N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinejcf.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.cardfail.2025.05.019","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T11:59:22Z","timestamp":1750679962000},"page":"1041-1049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Angiotensin Receptor Neprilysin Inhibitor in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Regurgitation: Design and Rationale of the PRAISE-MR Trial"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5615-3191","authenticated-orcid":false,"given":"SEBASTIAAN","family":"DHONT","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SARA MOURA","family":"FERREIRA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XAVIER","family":"GALLOO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PIETER","family":"MARTENS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EVELYNE","family":"MEEKERS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KATRIEN","family":"TARTAGLIA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00c9BASTIEN","family":"DEFERM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LIEVEN","family":"HERBOTS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WILFRIED","family":"MULLENS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FREDERIK H.","family":"VERBRUGGE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JAN","family":"VERWERFT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PHILIPPE B.","family":"BERTRAND","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2025.05.019_bib0001","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction: JACC Scientific Statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0002","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","author":"Packer","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0003","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0004","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1016\/j.jacc.2019.02.061","article-title":"Atrial functional mitral regurgitation: JACC Review Topic of the Week","volume":"73","author":"Deferm","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0005","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.jcmg.2022.08.016","article-title":"Atrial functional mitral regurgitation: A JACC: Cardiovascular Imaging Expert Panel Viewpoint","volume":"15","author":"Zoghbi","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0006","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/ejhf.562","article-title":"Functional mitral regurgitation at discharge and outcomes in patients hospitalized for acute decompensated heart failure with a preserved or reduced ejection fraction","volume":"18","author":"Kajimoto","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0007","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/ejhf.1699","article-title":"Functional mitral regurgitation and left atrial myopathy in heart failure with preserved ejection fraction","volume":"22","author":"Tamargo","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0008","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.jacc.2011.06.032","article-title":"Evidence of atrial functional mitral regurgitation due to atrial fibrillation: reversal with arrhythmia control","volume":"58","author":"Gertz","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0009","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"43","author":"Vahanian","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0010","first-page":"E72","article-title":"2020 ACC\/AHA Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0011","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0012","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0013","doi-asserted-by":"crossref","first-page":"H289","DOI":"10.1152\/ajpheart.00579.2018","article-title":"Synergy between sacubitril and valsartan leads to hemodynamic, antifibrotic, and exercise tolerance benefits in rats with preexisting heart failure","volume":"316","author":"Maslov","year":"2019","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0014","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1161\/CIRCULATIONAHA.122.061693","article-title":"Association between sacubitril\/valsartan initiation and mitral regurgitation severity in heart failure with reduced ejection fraction: the PROVE-HF study","volume":"146","author":"Januzzi","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0015","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/CIRCULATIONAHA.118.037077","article-title":"Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation","volume":"139","author":"Kang","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0016","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1161\/CIRCULATIONAHA.122.061693","article-title":"Association between sacubitril\/valsartan initiation and mitral regurgitation severity in heart failure with reduced ejection fraction: the PROVE-HF Study","volume":"146","author":"Januzzi","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0017","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0018","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1001\/jamacardio.2023.0065","article-title":"Effect of sacubitril\/valsartan vs valsartan on left atrial volume in patients with pre-heart failure with preserved ejection fraction: the PARABLE randomized clinical trial","volume":"8","author":"Ledwidge","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0019","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1001\/jama.2021.18463","article-title":"Effect of sacubitril\/valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: the PARALLAX randomized clinical trial","volume":"326","author":"Pieske","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0020","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0021","first-page":"E895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","article-title":"Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure","volume":"82","author":"Mentz","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0023","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1093\/eurheartj\/ehad344","article-title":"Sacubitril\/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF","volume":"44","author":"Vaduganathan","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0024","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3390\/jcm12031086","article-title":"Left atrial functional remodeling in patients with chronic heart failure treated with sacubitril\/valsartan","volume":"12","author":"Correale","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0025","doi-asserted-by":"crossref","first-page":"19943","DOI":"10.1073\/pnas.1106954108","article-title":"Cyclic strain induces dual-mode endothelialmesenchymal transformation of the cardiac valve","volume":"108","author":"Balachandran","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0026","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.jacc.2017.07.734","article-title":"Effect of losartan on mitral valve changes after myocardial infarction","volume":"70","author":"Bartko","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0027","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1093\/ehjci\/jeae239","article-title":"Exercise-Induced pulmonary hypertension: rationale for correcting pressures for flow and guide to non-invasive diagnosis","volume":"25","author":"Dhont","year":"2024","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0028","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jacc.2019.10.048","article-title":"Exercise pulmonary hypertension predicts clinical outcomes in patients with dyspnea on effort","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0029","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0030","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.jacc.2017.08.012","article-title":"Cardiopulmonary exercise testing: What is its value?","volume":"70","author":"Guazzi","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0031","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1093\/eurheartj\/ehad141","article-title":"Heart failure with preserved ejection fraction: relevance of a dedicated dyspnoea clinic","volume":"44","author":"Verwerft","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0032","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jcmg.2015.06.018","article-title":"Accuracy of echocardiography to evaluate pulmonary vascular and rv function during exercise","volume":"9","author":"Claessen","year":"2016","journal-title":"JACC Cardiovasc Imag"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0033","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s12265-021-10142-8","article-title":"cardiopulmonary exercise testing with echocardiography to identify mechanisms of unexplained dyspnea","volume":"15","author":"Martens","year":"2022","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0034","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jchf.2022.11.004","article-title":"Cardiopulmonary exercise testing with simultaneous echocardiography: blueprints of a dyspnea clinic for suspected HFpEF","volume":"11","author":"Verwerft","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0035","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1002\/ehf2.13561","article-title":"Percutaneous edge-to-edge mitral valve repair for mitral regurgitation improves heart failure symptoms in heart failure with preserved ejection fraction patients","volume":"8","author":"Gr\u00f6ger","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cardfail.2025.05.019_bib0036","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/eurheartj\/ehab086","volume":"42","author":"Coats","year":"2021","journal-title":"Eur Heart J"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916425002878?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916425002878?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T10:55:46Z","timestamp":1781002546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916425002878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1071916425002878"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2025.05.019","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angiotensin Receptor Neprilysin Inhibitor in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Regurgitation: Design and Rationale of the PRAISE-MR Trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2025.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}